Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

Background Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	F. Stephen Hodi, Pasi A. Janne, Mark M. Awad, Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2016-12-01
Online Access:	https://jitc.bmj.com/content/4/1/84.full